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 Introduction 
 Toxic epidermal necrolysis (TEN) is a 
rare cutaneous adverse drug reaction, with 
a mortality of around 30%  [1] . Prior drug 
intake is reported in over 95% of patients 
with TEN, and a strong association is ob-
served in 80% of cases  [2, 3] . Other, rarer 
causes include infections and immuniza-
tions. To date, more than 100 drugs have 
been associated with the development of 
TEN, the most frequent being allopurinol, 
antibiotics, nonsteroidal anti-inflammato-
ry drugs and anticonvulsants  [3] . Self-med-
ication with phytotherapeutics has become 
increasingly popular, and due to their 
availability, their abusive use is increasing. 
We describe a patient with TEN most like-
ly triggered by the regular use of the herb 
fenugreek.
 Case Report 
 A 32-year-old female presented to a re-
gional hospital with fever, headache and 
beginning exanthema. She had given birth 
to her second child, without any complica-
tions, 1 month prior to admission. The pa-
tient’s medical history included the ir-
regular intake of metamizole, paracetamol 
 (acetaminophen) and ibuprofen since giv-
ing birth. Additionally, she regularly took a 
herbal preparation made of pure fenugreek 
seeds to improve lactation. All medications 
except for fenugreek had been taken by the 
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 Abstract 
 We describe the case of a 32-year-old wom-
an who presented to the hospital with gen-
eralized painful exanthema, blisters and 
erosions 1 month after giving birth to a 
healthy girl. The patient’s medical history 
was inconspicuous for comorbidities; how-
ever, it included the incidental intake of pain 
killers and a herbal preparation (fenugreek), 
which she took regularly over the last 4 
weeks to improve lactation. Based on the 
clinical characteristics, we suspected toxic 
epidermal necrolysis (TEN), a severe cutane-
ous adverse drug reaction, which was con-
firmed by skin biopsy. The patient was treat-
ed with high-dose intravenous human im-
munoglobulins and was discharged 2 weeks 
after hospital admission in good condition. 
The allergological workup identified fenu-
greek as the most likely causative agent. Giv-
en the increased self-medication of freely 
available phytotherapeutics by patients in 
industrialized countries, herbal mixtures 
should be taken into consideration in the di-
agnostic workup of TEN. 
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patient during her previous pregnancy 
without the appearance of any adverse re-
actions. The patient was first diagnosed 
with a common cold and sent back home. 
Due to the deterioration of her general con-
dition with spreading exanthema on the 
face and upper trunk, the patient was trans-
ferred to the University Hospital with the 
suspected diagnosis of severe cutaneous 
adverse drug reaction. On admission, she 
presented with multiple bullae and ero-
sions with a positive Nikolsky sign and skin 
sloughing involving approximately 30–
40% of her body surface including the 
mouth, lips and tongue ( fig. 1 ). There was 
no involvement of the eyes, genital mucosa 
or other mucosal areas. Two biopsies were 
performed, and both confirmed the diag-
nosis of TEN with completely necrotic epi-
dermis with mixed-cell inflammatory infil-
trates in the histological sections. The se-
verity-of-illness score (SCORTEN) was 2, 
with a predicted mortality of 3%  [4, 5] . 
Treatment with intravenous high-dosed 
immunoglobulins (IVIg) at a total dose of 
3 g/kg body weight was initiated and con-
tinued over the following 3 days together 
with supportive treatment at the intensive 
care unit. In the following days, the pa-
tient’s condition markedly improved, and 
she was finally discharged 2 weeks later af-
ter full recovery. In order to identify the 
causative agent, an allergologic workup 
was performed 4 months after full recov-
ery. Lymphocyte transformation tests 
(LTT) demonstrated a significant sensiti-
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zation for fenugreek without any prolifera-
tion of immune cells in the presence of 
metamizole, paracetamol and ibuprofen 
( table 1 ). However, it should be noted that 
the LTT are not a standardized procedure 
and merely demonstrate the proliferation 
of lymphocytes in the presence of various 
compounds. Skin patch tests were not per-
formed because the rate of positive test re-
actions in Stevens-Johnson syndrome 
(SJS)/TEN is rather low with 24%  [6] . Due 
to the risk of severe side effects after TEN, 
we did not apply oral provocation tests. 
Based on the LTT, fenugreek was identified 
as the most likely causative agent, despite 
the fact that infectious agents (e.g. certain 
viruses) cannot be ruled out completely as 
causative agents or cofactors of TEN. As 
drug hypersensitivity to metamizole, 
paracetamol and ibuprofen cannot be ex-
cluded without provocation testing, we ad-
vised against the intake of all three pain 
killers as well as of fenugreek in the future. 
 Discussion 
 Today, SJS and TEN are regarded as be-
ing different manifestations in degrees of 
severity of one and the same rare, acute and 
life-threatening mucocutaneous disease, 
which is nearly always drug related  [1] . In 
this context, TEN represents the severest 
form of this pathological entity. TEN is a 
consequence of extensive keratinocyte cell 
death that results in the separation of sig-
nificant areas of skin at the dermal-epider-
mal junction, producing the appearance of 
scalded skin. This massive cell death results 
in mucous membrane detachment and 
contributes to the characteristic symptoms 
of TEN, which include high fever, skin 
pain, anxiety and asthenia  [1] . In terms of 
pathogenesis, TEN is thought to be the 
consequence of an altered immune re-
sponse to an antigenic drug-tissue com-
plex, although the exact pathophysiologic 
mechanism(s) are still unclear. Today, 
three different concepts on how the anti-
genic drug-tissue complex is formed exist 
 [7] : (a) covalent binding of a drug to a cel-
lular peptide (hapten/prohapten concept), 
(b) noncovalent, direct interaction of a 
drug with a specific major histocompatibil-
ity complex (MHC) I allotype (p-i con-
cept), and (c) presentation of an altered-
self repertoire by direct drug-MHC I inter-
action (altered peptide concept). Whereas 
the well-known hapten model is less likely 
to be human leukocyte antigen (HLA) re-
 Table 1.  Lymphocyte transformation test positive for fenugreek
Compound Concentration, 
μg
SI (autologous 
plasma)
SI (AB 
plasma)
Paracetamol 0.1 1.3 1
1 1.2 1
10 1 0.9
100 0.9 0.8
500 0.8 1.3
Ibuprofen 0.1 0.8 1.3
1 1 1.3
10 1.1 1.6
100 0.8 0.8
Metamizole 0.1 0.6 0.8
1 1 0.9
10 1.5 1
100 0.9 0.5
Fenugreek 100 86.9 1.3
1,000 17.5 3.2
Tetanus (positive control) 1 125.9 108.9
 SI = Stimulation index; AB plasma = human, antibody-free, plasma blood type AB.
a
bc
 Fig. 1. TEN triggered by fenugreek.  a Detachment of large sheets of necrolytic epidermis 
(>30% body surface area), leading to extensive areas of denuded skin.  b A few intact bul-
lae are still present.  c Hemorrhagic crusts with mucosal involvement. 
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stricted, the other two concepts favor spe-
cific HLA phenotypes  [8–10] . In line with 
the concepts of HLA-restricted drug pre-
sentation are reports on the genetic suscep-
tibility, as evidenced by the identification 
of specific drug-related HLA alleles as ma-
jor susceptibility genes for the develop-
ment of SJS and TEN  [11–13] . However, it 
should be noted that most HLA pheno-
types associated with SJS/TEN are of rele-
vance for people of Han-Chinese or South 
East Asian ancestry only. As a result of im-
mune activation by the drug-tissue com-
plex, an interplay of various cell types and 
cytokines (yet to be defined) is initiated 
that is accompanied by a strong expression 
of the cytolytic molecule FasL on keratino-
cytes as well as granulysin and annexin A1 
secretion from cytotoxic T lymphocytes, 
natural killer cells, natural killer T cells and 
monocytes  [14–19] . This leads to FasL- and 
granulysin-mediated apoptosis and/or an-
nexin-dependent necroptosis of keratino-
cytes and subsequent epidermal necrosis 
and detachment. Of note, granulysin is ex-
pressed at high concentrations in the blis-
ter fluid of TEN patients, suggesting an im-
portant role of this protein in the patho-
genesis of TEN  [17] .  
 To date, no specific therapies for TEN 
have shown efficacy in prospective, con-
trolled clinical trials. Case reports and case 
series have reported the use of cyclospo-
rine, cyclophosphamide, plasmapheresis, 
N-acetylcysteine, tumor necrosis factor-α 
antagonists (e.g. etanercept, infliximab), 
systemic corticosteroids and thalidomide 
[for a review, see  1 ]. In our case, we treated 
the patient with high-dose IVIg (>2 g/kg 
bodyweight total). Even though the mech-
anism of action is still unclear, with con-
firmed diagnosis as well as for severe TEN, 
early administration of high-dose IVIg 
may be considered  [1, 20] . Interestingly, it 
has been shown that IVIg do not reduce the 
levels of granulysin. This might be, at least, 
partly responsible for the lack of efficacy of 
IVIg in some patients  [21, 22] . Alternative-
ly, a recent study has shown excellent effi-
cacy of cyclosporine in the treatment of 
TEN  [23, 24] .
 Although TEN is mostly caused by pre-
scribed drugs, we report the first case of 
TEN due to fenugreek. Fenugreek belongs 
to the family of Fabaceae and is used as a 
herb (dried or fresh leaves), spice (seeds) 
and vegetable (fresh leaves) in the Indian 
subcontinent, Argentina, Egypt, France, 
Spain and Turkey. Fenugreek is a popular 
phytotherapeutic and is thought to have 
beneficial effects in multiple sclerosis, dia-
betes, cancer and lactation although its 
mode of action is unknown, and controlled 
clinical trials are missing. Fenugreek seeds 
consist of approximately 50% fiber (fenu-
greekine), 20% gums, 20% proteins, be-
sides moisture, lipids, starch and ash. Ad-
ditionally, chemical analyses have identi-
fied alkaloids and various sapogenins as 
part of fenugreek seeds. The antigenic parts 
of fenugreek are still unknown, but specific 
IgE binding with the fenugreek proteins in 
immunoblotting has been reported in 2 pa-
tients allergic to fenugreek and in mice sen-
sitized to fenugreek  [25, 26] . Not much is 
known about the adverse cutaneous side ef-
fects of fenugreek intake. A prospective ob-
servational study conducted in Bangladesh 
analyzed a total of 29 patients with TEN ad-
mitted to the intensive care unit  [27] . In 10 
patients (34%), the causative agent remains 
unidentified. However, those patients had 
treated themselves with several traditional 
herbal drugs to cure fever before the onset 
of TEN. Those herbal mixtures included 
 Ocimum, Tribulus, Caesalpinia, Tinospora, 
Piper, Cichorium and  Foeniculum . As  Cae-
salpinia and fenugreek belong to the same 
plant family, namely Fabaceae, one can 
speculate that severe cutaneous adverse re-
actions were indeed triggered by herbal 
mixture in certain of those patients. The 
family of Fabaceae includes edible legumi-
nous plants (e.g. beans, soya beans, lentils 
and peanuts). Because cross-reactivity be-
tween certain leguminous plants is known 
in allergic patients, one has to consider the 
possibility of food allergy to leguminous 
plants in the patient’s allergological work-
up. However, as she had eaten beans, soya 
beans, lentils and peanuts in the meantime 
without any complications, secondary food 
allergy to legumes could be ruled out. We 
performed a thorough literature search on 
phytotherapeutics as triggers of SJS and 
TEN. We identified 4 case reports and 1 co-
hort study including 10 patients  [27–31] . 
In those reports, SJS and TEN were de-
scribed to be caused by the intake of tradi-
tional medications (Chinese roots and 
drinks), herbal ointment containing real-
gar and ayurvedic drugs ( table 2 )  [27–31] . 
In an additional study utilizing large phar-
macovigilance data in Thailand from 2002 
 Table 2.  Severe cutaneous adverse reactions due to phytotherapeutics
Authors [Ref.] Type of report Phytotherapeutics Severity 
of reaction
Survival
Mochitomi et al. [29] case report Ophiopogon japonicus tuber (in Chinese health drink) SJS yes
Wu and Deng [31] case report realgar (in oral herbal medicine and herbal ointment) TEN no
Shivamurthy et al. [30] case report ayurvedic drugs (not further specified) TEN yes
Monk [28] case report ‘golden health blood-purifying tablets’ (contains extracts 
of red clover, burdock, queen’s delight, poke root, prickly 
pear, ash, sassafras bark and Passiflora)
SJS yes
Kumar Das et al. [27] prospective 
cohort study
Ocinum, Tribulus, Caesalpinia, Tinospora, Piper, 
Cichorium and Foeniculum
TEN 34% survived
Wechwithan et al. [32] pharmacovi-
gilance study
Andrographis, green traditional medicine, Derris scandens SJS not reported
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to 2013, the authors computed that 0.001% 
of all reported serious adverse drug reac-
tions were due to Thai traditional medi-
cine. Of those, green traditional medicine 
was associated with an increased odds ratio 
in terms of SJS  [32] . Taken together, it is 
important to consider herbal medication as 
a possible trigger of severe cutaneous ad-
verse reactions like SJS and TEN as phyto-
therapeutics are becoming more popular in 
industrialized countries and are easily 
available.
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